Total contract income for the first half a year of 2014 was $112.5 million, a rise of 16 percent compared to contract revenue of $97.3 million for the same period in 2013. Royalty revenue for the initial six months of 2014 was $15.0 million, a decrease of 30 percent from $21.4 million in 2013.8 million from the net product sales of certain amphetamine salts sold by Actavis. Net gain under U.S. GAAP for the 1st half of 2014 was $7.2 million, or $0.22 per diluted share, compared to U.S. GAAP net income of $3.8 million, or $0.12 per diluted share for the first fifty % of 2013.The techniques we used for DNA extraction, PCR amplification, and sequencing are defined in the Supplementary Appendix. The circumsporozoite proteins C-terminal and SERA-2 amplicons were sequenced on an Illumina MiSeq platform. All MiSeq and PacBio amplicon sequence data were submitted to the NCBI Sequence Browse Archive35 . Study Oversight The trial was sponsored by GlaxoSmithKline Biologicals, the manufacturer and programmer of the vaccine, and was funded by both GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative, which received a grant from the Melinda and Expenses Gates Foundation. Many of the educational authors, in collaboration with the four authors who are employed by GlaxoSmithKline Biologicals, designed the study and the analysis strategy.